Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vactosertib Monotherapy in Low/Intermediate MDS
NCT03074006Phase 1Completed
- Sponsor
- MedPacto
- Start
- Jan 2018
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of vactosertib in myelodysplastic syndrome (MDS) (2 arms), sponsored by MedPacto. Primary endpoints: Maximum Tolerated Dose at 4 weeks and Hematologic Improvement at 16 weeks. Started Jan 2018; status: completed.
02
Drugs
vactosertib
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT03074006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03074006.